HK Stock Market Move | JUNSHI BIO (01877) rose over 7% in early trading, application for approval of Tropuli monoclonal antibody injection (subcutaneous injection) has been accepted.

JUNSHI BIO (01877) rose by over 7% in early trading, as of the time of writing, it has increased by 6.54% to 20.2 Hong Kong dollars, with a trading volume of 21.4932 million Hong Kong dollars. On the news front, according to JUNSHI BIO, the company's independently developed Toripalimab monoclonal antibody injection subcutaneous injection formulation (JS001sc) for the treatment of tumors has submitted applications for listing for 12 indications and has been accepted by the National Medical Products Administration. This product is the first domestically produced subcutaneous formulation of an anti-PD-1 monoclonal antibody to enter the listing application stage, and is expected to significantly improve the convenience of tumor immunotherapy. The 12 indications applied for this time cover all the indications that Toripalimab monoclonal antibody has been approved for in mainland China, including non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma, esophageal cancer, kidney cancer, liver cancer, and other various tumors. Compared to the current mainstream intravenous infusion, the subcutaneous injection formulation will shorten the administration time, optimize the treatment experience for patients, and allocate medical resources more efficiently.